|
|
800 Bellevue Way, Suite 400
Bellevue, Washington 980054 USA
phone:(425) 462-2556
fax:
|
|
| Symbol |
OTC-BB |
| Exchange |
|
| Founded |
2001 |
| Employees |
3 |
|
|
| www.tapimmune.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutics and vaccines in the areas of oncology and infectious disease |
|
| Management |
Glynn Wilson, Ph.D., Executive Chairman
Dr. Wilson's former positions include Head of Drug Delivery at SmithKline Beecham Pharmaceuticals, Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals, and others. Glynn has a Ph.D. in Biochemistry and conducted medical research at The Rockefeller University, New York.
Denis D Corin, President
Denis Corin is a management consultant with experience in pharmaceutical (Novartis), diagnostic instrumentation companies (Beckman Coulter) as well as the small cap biotech arena (MIV Therapeutics). BSocSci Economics and Marketing. |
| |
|
|
|
|
|
|
|
| Keywords |
| Therapeutics, vaccines, oncology, infectious disease |
|
|
|
| Description |
|
TapImmune is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company�s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. The Company�s vaccine has shown effective restoration of TAP and subsequent recognition and killing of cancer cells by the immune system. The TAP vaccine also works to enhance targeted vaccines against infectious diseases. |
|
| Products / Services |
AdhTAP therapeutic vaccine for carcinomas & melanomas - The action of the TAP vaccine re-establishes the presentation of tumor antigens on the MHC class I molecule thus identifying the cancer to the cellular arm of the immune system.
TapImmune?s Prophylactic vaccine platform demonstrates that even low, suboptimal doses of vaccines, confers protective immunity against lethal viral loads during viral challenges. This paradigm shift could significantly advance the development of new vaccines as well as improve those that already exist.
|
|
| Technology / Differentiation |
TapImmune?s therapeutic unspecific cancer vaccine represents a conceptual leap in the design of therapeutic cancer vaccines. In preclinical studies, this vaccine has been shown to greatly increase the sensitivity of the immune system to recognize and destroy cancerous cells.
TapImmune?s prophylactic vaccine utilizes components of the major histocompatibility class I antigen processing pathway in order to increase the immune priming and protection against foreign pathogens making the production and utilization of vaccines much more responsive in times of acute need. |
|
| Market / Customers |
The company is currently developing TAP based vaccines for the oncology and prophylactic market. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.
|
|
| Status |
| Pre-Clinical. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
